Zhangweiying

Research of Zhang has focused on the mechanism of the development of tumor and screening new drugs of anti-cancer. Currently there are severral projects on going in her program. One project deals with the molecular mechanism of the development of HCC. Second one focuses on the mechanism of new oncoprotein HBXIP in the regulation of abnormal glucose and lipid metabolism of breast cancer. Third one concerns the research and development of new drugs of anti-cancer. Since 2009, she has published 44 SCI original research articles in Science Signaling, Molecular Cancer, Cancer Research, Oncogene, Carcinogenesis, Cancer letters, J.B.C, Neoplasia, and others. As a first author or corresponding author, she published 21 SCI original research articles in Science Signaling, Molecular Cancer, BBRC and APS.She wrote two books on Hepatitis B Virus Research published in Nova Publisher of America.

Mar.2013-Jun.2014 Postdoc. Medical Center, Georgetown University Sep.2004-Jul.2009 Ph.D., Dept. of Biochemistry and Molecular Biology, Nan Kai University, Tianjin, China Sep.1997-Jul.2001 B.Sc., Dept. of Biology, Inner Mongolia University, Hohhot, China

Jul.2009-now Assistant Professor, Dept. of Biochemistry and Molecular Biology, Nan Kai University, Tianjin, China Mar.2007-Sep.2007 Visiting scholar, Dept. of Biochemistry, Hong Kong University of Science and Technology, Hong Kong, China Jul.2001-Sep.2004 Employee, Dept. of Market of Peking Science Company, Peking, China

Research on Molecular Mechanism of Occurrence, Development and Metastasis of Breast and Liver Cancer

Research on Anti-breast and Anti-liver cancer Drug Targets

New Anti-cancer Drug Research & Development

 

 

 

 

 

 

Funding

lNational Natural Science Foundation of China (No. 82072929, 81000870)

lNational High Technology Research and Development Program of China (863 Program, 2014AA020903)

lFundamental Research Funding for the Central Universities (65010671)

 

 

Selected Publications

1.      Fei-Fei Xu, Hui-Min Sun, Run-Ping Fang, Lu Zhang, Hui Shi, Xue Wang, Xue-Li Fu, Xian-Meng Li, Xu-He Shi, Yue Wu, Kai Ye, Wei-Ying Zhang*, Li-Hong Ye*. The modulation of PD-L1 induced by the oncogenic HBXIP for breast cancer growth. Acta Pharmacol Sin. 2022 Feb;43(2):429-445.

2.    Yue Wu, Xue Wang, Feifei Xu, Lu Zhang, Tianjiao Wang , Xueli Fu, Tianzhi Jin, Weiying Zhang*, Lihong Ye*. The Regulation of Acetylation and Stability of HMGA2 via the HBXIP-activated Akt-PCAF Pathway in Promotion of Esophageal Squamous Cell Carcinoma Growth. Nucleic Acids Res. 2020 May 21;48(9):4858-4876.

3.       Wang T, Fu X, Jin T, Zhang L, Liu B, Wu Y, Xu F, Wang X, Ye K, Zhang WY*, Ye LH*. Aspirin targets P4HA2 through inhibiting NF-κB and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma. EBioMedicine. 2019 Jul;45:168-180. 

4.   Liu BW, Wang TJ, Li LL, Zhang L, Liu YX, Feng JY, Wu Y, Xu FF, Zhang QS, Bao MZ, Zhang WY*, Ye LH*. Oncoprotein HBXIP induces PKM2 via transcription factor E2F1 to promote cell proliferation in ER-positive breast cancer.Acta Pharmacol Sin. 2019 Apr;40(4):530-538.

5.      Li H, Wang Z, Jiang M, Fang RP, Shi H, Shen Y, Cai XL, Liu Q, Ye K, Fan SJ*, Zhang WY*, Ye LH*. The oncoprotein HBXIP promotes human breast cancer growth through down-regulating p53 via miR-18b/MDM2 and pAKT/MDM2 pathways. Acta Pharmacol Sin. 2018 Nov;39(11):1787-1796.

6.      Liu B, Wang T, Wang H, Zhang L, Xu F, Fang R, Li L, Cai X, Wu Y, Zhang WY*, Ye LH*. Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer. J Hematol Oncol. 2018 Feb 23;11(1):26.

7.      Cai X, Wang X, Cao C, Gao Y, Zhang S, Yang Z, Liu Y, Zhang X, Zhang W*, Ye L*. HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g. Cancer Lett. 2018 Feb 28;415:11-19.

8.       Li H, Wang Z, Li Y, Fang R, Wang H, Shi H, Zhang X, Zhang WY*, Ye LH*. Hepatitis B X-interacting protein promotes the formation of the insulin gene-transcribing protein complex Pdx-1/NeuroD1 in animal pancreatic β cells. J Biol Chem. 2018 Feb 9;293(6):2053-2065.

9.       Feng GX, Li J, Yang Z, Zhang SQ, Liu YX, Zhang WY*, Ye LH*, Zhang XD*. Hepatitis B virus X protein promotes the development of liver fibrosis and hepatoma through downregulation of miR-30e targeting P4HA2 mRNA. Oncogene. 2017 Dec 14;36(50):6895-6905.

10.   Feng G, Shi H, Li J, Yang Z, Fang R, Ye L, Zhang WY*, Zhang XD*. MiR-30e suppresses proliferation of hepatoma cells via targeting prolyl 4-hydroxylase subunit alpha-1 (P4HA1) mRNA. Biochem Biophys Res Commun. 2016 Apr 8;472(3):516-22.

11.   Zhang WY#, Lu Z#, Gao Y, Ye LH, Song TQ*, Zhang XD*. MiR-520b suppresses proliferation of hepatoma cells through targeting ten-eleven translocation 1 (TET1) mRNA. Biochem Biophys Res Commun. 2015 May 8; 460(3):793-8.

12.   Zhang WY, Lu Z, Kong G, Gao Y, Wang T, Wang Q, Cai N, Wang H, Liu F, Ye L and Zhang X. Hepatitis B virus X protein accelerates hepatocarcinogenesis with partner survivin through modulating miR-520b and HBXIP. Mol Cancer.2014 May 28, 13:128.

13.   Zhang WY, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G, Gupta S, Vietsch EE, Laughlin SZ, Wadhwa M, Chetram M, Joshi M, Wang F, Kallakury B, Toretsky J, Wellstein A, Yi C. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal. 2014 May 6 ;7(324):ra42.

14.   Zhang WY#, Kong G^#, Zhang J, Wang T, Ye LH*, Zhang XD*. MicroRNA-520b inhibits growth of hepatoma cells by targeting MEKK2 and Cyclin D1. PLoS One 2012 Feb 3;7(2): e31450.

15.   Zhang WY, Cai N, Ye LH*, Zhang XD*. Transformation of human liver L-O2 cells mediated by stable HBx transfection. Acta Pharmacol Sin. 2009 Aug; 30(8):1153-61.

Undergraduate course <Molecular Biology>

Post-graduate course <Advanced Biochemistry>